EVER Pharma gained EU-Approval for Advanced Cancer Treatment

EVER Pharma, a fully integrated specialty pharmaceuticals company, announced the approval of Eribulin in the European Union. Eribulin is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma¹.

Despite advances in early detection and treatment, metastatic breast cancer remains untreatable, typically resulting in a median overall survival of approximately 2-3 years². For patients diagnosed with earlier stages of breast cancer, approximately 30% will eventually develop recurrent advanced or metastatic disease³. Eribulin provides an important second treatment option for these patients after failure of first‐line treatment.

Liposarcoma is a rare form of cancer where treatment usually involves surgery to remove the cancer. However, it poses a significant health challenge with 40% to 50% of patients developing metastatic disease and surgical treatment no longer being possible⁴. Eribulin is considered a key drug in treating these patients when a first‐line chemotherapy has failed.

Georges Kahwati, General Manager of EVER Pharma, expressed his enthusiasm, stating, “We are delighted with the approval of Eribulin in the EU, which underscores our commitment to provide highly specialized pharmaceuticals for patients worldwide.”

The addition of Eribulin to EVER Pharma’s expanding specialty injectables portfolio demonstrates its commitment to developing and providing a broad range of oncology treatments. Eribulin EVER Pharma will be rolled out on a global basis to ensure broad access to this important therapy for patients in need.